Direct comparative efficacy studies are few, and also may have design issues, which make their interpretation difficult. The most serious safety issues for monoclonal antibodies include the risk ...

Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM) ...

Researchers have developed a new microscopic method to observe the interactions of therapeutic antibodies with target molecules on tumor cells.

Monoclonal Antibody to Inhibit IL33 for Autoimmune Disorders is under clinical development by Eli Lilly and Co and currently in Phase I for Autoimmune Disorders.